SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has sponsored a supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM) focusing on classic congenital adrenal hyperplasia (CAH), ...

such as late-onset congenital adrenal hyperplasia and Cushing's syndrome. The more recent 2003 Rotterdam consensus workshop was in response to an increasing awareness that the clinical expression ...

Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Across Doses, Including up ...

capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal ...

Crinetics Pharmaceuticals announced positive topline results from a Phase 2 study of atumelnant, a novel oral ACTH receptor antagonist, for treating congenital adrenal hyperplasia (CAH).

Jefferies has upgraded Crinetics Pharmaceuticals (NASDAQ:CRNX) to buy, citing a recent pullback in the stock on investor concerns about Phase 2 data for the company's drug atumelnant in the treatment ...

Pharmaceuticals announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia, CAH, study of ...

Jefferies analyst Dennis Ding upgraded Crinetics (CRNX) to Buy from Hold with an unchanged price target of $55. The firm cites the pullback in ...

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH ...